Evaluation of Two Commercially Available DNA Tests for Detection of Human Papillomavirus by Halstead, Diane C. et al.
Infectious Diseases in Obstetrics and Gynecology 2:255-262 (1995)
(C) 1995 Wiley-Liss, Inc.
Evaluation of Two Commercially Available DNA Tests
Detection of Human Papillomavirus
Diane C. Halstead, Sharon L.H. Pfleger, and William Dupree
Microbiology Division (D.C.H.), Pathology Department (W.D.), Lehigh Valley Hospital,
Allentown, PA, and Microbiology Division (S.L.H.P.), Warren Hospital, Phillipsburg, NJ
ABSTRACT
Objective: This study was designed to compare the sensitivity, specificity, efficiency, positive and
negative predictive values, and ease of use for 2 commercially available hybridization kits for
detecting human papillomavirus (HPV) DNA: Oncor Southern blot (SB) (Oncor, Inc., Gaithers-
burg, MD) and Digene ViraType dot blot (DB) (Digene Diagnostics, Inc., Silver Spring, MD).
Methods: A total of 179 specimens (172 cervical and 7 penile biopsies) were assessed for accept-
ability based on the presence of epithelial cells and tested forHPV by DB and SB. The results were
evaluated based on Papanicolaou-stained cervical specimens and selected risk factors.
Results: One hundred six (97.2%) of 109 results were concordant, i.e., 93 negative (85.3%) and 13
positive (11.9%). Using SB as the gold standard, we found the sensitivity, specificity, efficiency, and
positive and negative predictive values for the ViraType DB to be 100%, 96.9%, 97.3%, 81.3%, and
100%, respectively. Comparing the Papanicolaou smear to SB and DB, we found the sensitivity,
specificity, efficiency, and positive and negative predictive values to be 33.3% (SB) vs. 44.4% (DB),
89.5% vs. 87.6%, 87.3% vs. 84.2%, 11.8% vs. 23.5%, and 97.0% vs. 94.9%, respectively. The only
significant risk factor for predicting an HPV infection was the number of sexual partners.
Conclusions: Although SB has been considered the standard model, DB is an acceptable method
for detecting and identifyingHPV infections. (C) 1995 Wiley-Liss, Inc.
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uring the last 10 years, there have been major
changes in the methods used to diagnose and
manage cervical squamous-cell cancer and its pre-
cursors.
1-3 More recently, molecular, clinicopatho-
logic, viral, and DNA studies have continued to
demonstrate similarities between condyloma and
cervical intraepithelial neoplasia (CIN) I and be-
tween CIN II and CIN III.
4 These similarities are
reflected in the Bethesda System for reporting Pa-
panicolaou-stained smears which divides the spec-
trum of morphologic squamous changes into low-
grade squamous intraepithelial lesion (SIL)
(condyloma, CIN I) and high-grade SIL (CIN II,
CIN III).
s There is almost universal agreement
that untreated patients with high-grade SIL, espe-
cially those with the equivalent of CIN III, are at
significantly elevated risk of developing invasive
squamous-cell carcinoma over time.
The natural history of low-grade SIL is much
more controversial, although a consensus is emerg-
ing that most low-grade SILs have a high spontane-
ous regression rate and are unlikely to progress to
invasive cancer.
6 Despite this generally favorable
view of low-grade SIL, many published prospec-
tive studies document cases of low-grade SIL that
have seemingly evolved into high-grade lesions. 7’8
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Further confounding the issue is the fact that
statements in regard to the natural history of SILs
are based on population statistics. Hence, the indi-
vidual patient and her physician are faced with a
probability statement as to what her unique course
might be. What is needed is a means to determine
which individual low-grade SILs will progress or
persist and which will regress.
Although unequivocal evidence establishing that
human papillomavirus (HPV) alone is the cause of
cervical cancer and its precursor lesions is lacking,
the strong association between HPV infection and
these disease processes spurs intense efforts to better
define the pathogenetic role of HPV. 6’9 Of >70
different types of HPV that infect humans, >20
have a predilection for the genital tract.
10 These
can be divided into 3 groups: those with little or
no oncogenic risk, those with an intermediate
oncogenic risk, and those with a high oncogenic
risk.
1 Based on a stratification ofHPV types into
oncogenic risk groups, Reid and Lorincz
12 have
suggested that determining which patients with
low-grade SIL will require treatment and which
may be followed should be based in part on the use
of HPV typing. These authors suggested that the
patients whose lesions were associated with low-
oncogenic-risk viral types might require neither
therapy nor close clinical follow-up, whereas those
lesions associated with high-oncogenic-risk HPV
types should be treated "appropriately." Lesions
with intermediate oncogenic viral types could be
closely followed prospectively. Apart from the po-
tential benefits for the patient, in an era of medical
cost containment, this type of triage protocol has
great appeal.
One of the problems associated with this triage
strategy has centered around the reported insensi-
tivity of commercially available HPV typing.
3
This study was designed to compare the sensitivity,
specificity, efficiency, positive and negative pre-
dictive values, and the ease of use for 2 commer-
cially available hybridization kits: Oncor Southern
blot (SB) (Oncor, Inc., Gaithersburg, MD) and
Digene ViraType dot blot (DB) (Digene Diagnos-
tics, Inc., Silver Spring, MD). These kits utilize
biotinylated and 32p-labeled RNA probes, respec-
tively. The results from these 2 methods were cor-
related with cytology findings and patient risk fac-
tors.
SUBJECTS AND METHODS
Specimens
A double-blind coded study was performed on a
total of 179 genital specimens collected between
May 1991 and February 1992. There were 172
cervical specimens, including 146 from a private
physician’s office and 26 from the Lehigh Valley
Hospital OB/GYN clinic, and 7 penile biopsies
from condylomatous lesions collected in an ambula-
tory surgical unit. The women were asked to sign
consent forms and to complete questionnaires in
order to assess their risk factors and clinical histo-
ries. The following information was obtained from
the questionnaire: age at first sexual encounter,
number of sexual partners, use of barrier protec-
tion, previous sexually transmitted disease(s), ab-
normal Papanicolaou smear(s), previous gyneco-
logical infections, family history of neoplastic
disease, and compromised immune system.
Specimen Collection and Processing
Exfoliated cervical cells were collected using a ster-
ile Christmas-tree cytobrush (Cat. #CYB, Medi-
cal Packaging Corp., Camarillo, CA). Three se-
quential cervical specimens were collected under
direct visualization. A smear for Papanicolaou stain-
ing was prepared from the first cervical specimen.
The remaining 2 specimens were placed in Digene
transport medium (Digene Diagnostics, Inc.) and
refrigerated for not more than 2 weeks, coded,
evaluated for adequacy, and frozen at -70C be-
fore processing. The biopsy specimens were hand-
delivered to the laboratory in sterile tubes, coded,
and frozen in phosphate-buffered saline at -70C
before processing.
The Papanicolaou smears were reviewed by a
member of the cytology staff and a cytopathologist
in accordance with the Bethesda System of nomen-
clature. The results obtained from the smears were
placed into 7 categories for data analysis as follows:
1) normal; 2) infection, not HPV, bacteria/fungi;
3) inflammation with associated cell changes; 4)
squamous atypia ofundetermined significance, sug-
gest repeat; 5) SIL-L (CIN I), condylomas, hyper-
keratosis or parakeratosis suggestive of HPV, or
koilocytes; 6) SIL-H (CIN II, CIN III), carci-
noma in situ (CIS); and 7) unacceptable. The pre-
vious cytology results were also noted.
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Each pair ofspecimens in transport medium was
vortexed prior to removal of the cytobrushes, com-
bined, and tested for adequacy by counting the
number of squamous and columnar epithelial cells/
low-power microscope field (lpf) in a wet-mount
preparation. A specimen was considered adequate if
at least an occasional cell (>1 cell/lpf) was ob-
served. Using the established criteria, we found
167/172 (97.1%) cervical specimens to be accept-
able. The results were not available for 3/5 remain-
ing specimens; 2 specimens were unacceptable. The
presence of blood was also noted. The combined
specimens were evenly distributed between 2 tubes
(approximately ml each) and frozen at -70C
until tested.
Oncor SB Procedure
The specimens were tested according to the manu-
facturer’s directions (Oncor, Inc.) using the Oncor
Probe Tech automated electrophoresis instrument.
The Oncor kit included "antisense" biotinylated
probes with nucleic-acid sequences complementary
to the entire viral genome of I-IPV types 6, 11, 16,
31,33, and 35 and E6/E7 early open-reading frame
(ORF) and L1 late ORF ofHPV 18.
The results were interpreted according to the
criteria established by Oncor. High and low con-
centration controls were used to identify the HPV-
type specific bands. The procedure allows the iden-
tification of types 6, 11, 16, 18, 31, 33, and 3 5. If
a sample did not form a band consistent with one of
these HPV types, it was recorded as an "other"
HPV type.
Digene ViraType DB Procedure
The ViraType kit was obtained from Digene Diag-
nostics, Inc. The kit includes 32p-labeled RNA
probes for the detection ofHPV groups 6/11, 16/
18, and 31/33/35. The probes are prepared by in
vitro transcription ofrecombinant plasmid contain-
ing nearly the entire DNA sequences of HPV.
With the exception of 2 specimens, visibly bloody
specimens were not tested, according to the manu-
facturer’s recommendations.
To determine the HPV type in a specimen, we
compared the autoradiographic signal that was gen-
erated by the specimen with the positive control for
the corresponding HPV probe group. Any signal
greater than the negative control was considered
positive. To distinguish between infection with a
single type and one with multiple types, we com-
pared the signals obtained with each positive patient
blot and control. If the test specimen gave an auto-
radiographic signal with only one probe, the speci-
men was scored positive for that group of HPV
types, e.g., 16/18. Ifthe same specimen also exhib-
ited a signal with another probe, e.g., 31/33/35,
which was less than or equal to the signal produced
by the 16/18 positive control on the membrane
with the 31/33/35 probe, the specimen was scored
negative for 31/33/35. If the test specimen gave a
positive signal that was greater than the 16/18 pos-
itive control, a multiple infection could not be ruled
out.
Statistical Analysis
The statistical significance ofthe SB and DB results
was determined using Youden’s square. Contin-
gency tables were used to analyze the risk factors
and cytology results.
RESULTS
Correlation of SB and DB
One hundred seventy-nine specimens (172 cervical
specimens from females between the ages of 13 and
77 years and 7 penile biopsies) were collected for
HPV typing. A total of 109 specimens (102 cervi-
cal scrapings and 7 penile biopsies) were tested by
both SB and DB. Seventy additional specimens
were tested by either SB (54) or DB (16). Fifty-
four of the 172 cervical specimens were visibly
bloody and were not tested by DB because, accord-
ing to the manufacturer’s directions, bloody speci-
mens may produce false negative results. Sixteen
additional specimens were only tested by ViraType.
Sixteen ( 14.7%) ofthe specimens (9 cervical and
all 7 biopsies) were positive by either SB or DB.
Complete concordance between SB and DB assays
was obtained with 106/109 (97.3%) specimens: 93/
106 (87.7%) negative and 13/106 (12.3%) posi-
tive results. Three discordant specimens were posi-
tive by DB and negative by SB (Fig. 1). Using SB
as the gold standard, we found the DB method to
have sensitivity, specificity, efficiency, and posi-
tive and negative predictive values of 100%,
96.9%, 97.3%, 81.3%, and 100%, respectively
(P 0.000). All 7 penile biopsies were positive by
both methods. Table lists the HPV-type distribu-
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7 Biopsies 172 Cervical
Oncor & Digene Scraptngs and
100% Concordance Smears
179 TOTAL SPECIMENS
54 109 16
performed Oncor & Digene Performed
Oncor only (102 Cervical Digene only
(negative) & 7 Biopsies) (negative)
Oncor Digene
13 (4-) 96 (-) 16 (+)
7 (+) (+) 7 (+) (+)
Biopsies Cervicals Biopsies Cervicals
(+) Cytolo (-) (+) Cytolo
93 (-)
2 4 4
Fig. I. Results ofHPV nucleic-acid hybridization. Of a total
of 179 specimens, 109 (102 cervical, 7 biopsies) were tested
on both systems.
TABLE I. HPV-type distribution in
concordant specimens
HPV type Total
6 II 16 18 31 33 35 no.
Oncor SB 7 2 3 2 0 16
Digene DB 8 3 5 16
(50%) (18.8%) (31.2%)
Results are given in number of positives.
ative predictive values of the Papanicolaou smears
compared with SB were 33.3%, 89.5%, 87.3%,
11.8%, and 97.0% (P 0.085). Compared with
DB, they were 44.4%, 87.6%, 84.2%, 23.5%,
and 94.9% (P 0.010). Only the cytology results
compared with DB were statistically significant.
Based on this comparison, a Papanicolaou smear
does not appear to predict I-IPV infection.
Two of the specimens positive only by DB for
HPV types 6/11 and 16/18, respectively., also had
positive cytology smears for SIL-L low/suggestive
of I-IPV infection. An additional specimen positive
only by DB for I-IPV types 31/33/35 was smear
negative using the established criteria. There were
no specimens positive by SB and negative by DB.
Correlation With Biopsy Specimens
The histology results were available from cervical
biopsy specimens collected on 21/172 patients par-
ticipating in our study. Eight specimens were col-
lected prior to enrollment in the study and 13 were
collected after study completion. Ten of 21 patients
were negative for HPV by hybridization and bi-
opsy, while biopsy specimen was positive both
histologically and by SB (type 18) and DB (type
16/18). Eight of 21 patients had biopsy specimens
with condylomatous changes and/or koilocytosis,
but were negative for HPV by hybridization. One
of these specimens, however, tested positive for
I-IPV using a chemiluminescent molecular hybrid-
ization assay (Hybrid Capture System, Digene Di-
agnostics, Inc.) during a subsequent evaluation in
the author’s laboratory. Two of 21 patients had
positive SB and DB tests for type 6/11, but were
biopsy negative.
tion and percentage for the concordant specimens
without discrepancy. Two biopsy specimens were
positive for > type: I-IPV types 6, 16, 33 and
types 6, 16, respectively.
Comparison With Cytology
One hundred forty-nine (83.2%)of the 169 speci-
mens tested by SB and 114 (63.7%) specimens
tested by DB were compared with the cytology
results. There were 19/169 Papanicolaou smears
graded SIL-L. There were no smears graded
SIL-H or CIS in this patient population. The sen-
sitivity, specificity, efficiency, and positive and neg-
Correlation of Risk Factors
Of the 7 potential risk factors for predicting HPV
infection, only the number of lifetime partners was
statistically significant in our study. Based on the
logistic regression (Fig. 2) of the number of part-
ners, the probability of acquiring HPV, with
partner considered the norm, is 0.017, increasing
to 0.655 with 20 partners. The relative risk (Fig.
3) of acquiring HPV is 0.79 with 0 partners and
37.7 with 20 partners. For example, a person with
20 partners is 37 times more likely to become in-
fected with HPV compared with a person with
partner. The relative odds risk (Fig. 4) of acquir-
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Fig. 2. Using logistic regression, the probability of acquir-
ing HP, with partner as the norm being 0.017 and increas-
ing to 0.655 with 20 partners.
100
E 75
0’-
PartneP$
Fig. 4. Using 164 observations, the relative odds risk of
acquiring HPV 106 times greater with 20 partners than with
partner).
Fig. 3. Using 164 observations, the relative risk of acquir-
ingHP (0.79 with no partners and 37 times greater with 20
partners).
ing I-IPV is 106 times greater with 20 partners than
with partner.
DISCUSSION
Infection with papillomavirus is a rapidly growing
sexually transmitted disease in the United States
today. Because of its association with cervical carci-
noma, the ability to detect HPV in genital speci-
mens has become an important issue in the manage-
ment of patients with equivocal Papanicolaou
smears. Until recently, cytology has been the only
means of detecting potential HPV infection. Sev-
eral methods have been developed for use in the
clinical laboratory in order to detect the presence of
HPV in infected tissue as well as the HPV type
including SB, DB, in situ hybridization, and more
recently hybrid capture.
14 In this evaluation, we
compared the Oncor SB with the Digene DB tech-
nique to identify the presence of 7 of the most
common I-IPV types (6, 11, 16, 18, 31, 33, and
35) in cervical specimens and penile biopsies col-
lected from 179 patients. The SB method utilized
biotinylated nucleic-acid RNA probes for the detec-
tion of the individual HPV types and the DB uti-
lized 32p-labeled RNA probes for types 6/11, 16/
18, and 31/33/35. The ViraType DB, rather than
the ViraPap screening DB which utilizes a cocktail
of the same probes, was chosen because the manu-
facturer stated that the ViraType was more sensi-
tive. To date, reports comparing the results from
these 2 kits have not been published. In addition,
different risk factors and cytologic findings were
assessed to further determine which group of indi-
viduals would most benefit from I-IPV testing.
SB hybridization is considered the gold standard
for the identification of specific HPV types as well
as the identification of new types and subtypes,
although the SB procedure is technically challeng-
ing, labor intensive, and time-consuming, taking
approximately 5 days to complete a batch of speci-
mens. The Oncor procedure uses non-radiolabeled
probes, which permits a long shelf life. Attention
to detail and exact pipetting are required in order to
obtain bands that are easily interpreted. The speci-
mens collected in the Oncor transport medium must
be stored at 4C. The electrophoretic equipments’
cost and technologist’s time need to be considered
when deciding to use SB vs. DB, although the
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Oncor Probe Tech may be used for other molecu-
lar diagnostic tests such as gene rearrangement.
In contrast, the FDA-approved ViraType DB is
relatively easy to perform and fast, being com-
pleted in 8 h, exclusive of autoradiography. The
only equipment required are the manifolds and a
vacuum pump. As a convenience, the specimens
may be stored at room temperature for up to 2
weeks. A disadvantage of the DB method is the use
of radiolabeled probes, with a shelf life of <2
weeks. As with the SB method, for cost effective-
ness, specimens must be batched. According to the
manufacturer’s directions, bloody specimens may
cause false negatives. False positives, on the other
hand, may be caused by trapping of the probe by
specimens containing significant protein and cellu-
lar debris. Unlike the SB, the ViraType DB only
detects HPV groups 6/11, 16/18, and 31/33/3 5,
rather than the individual types. However, the
results may still provide the physician who wishes
to test for HPV with information that can be used
in patient management. An HPV-profile DB as-
say, which utilizes 2 probes (1 to identify low-risk
I--IPV types 6, 11, 42, 43, and 44 and the other to
detect intermediate and high-risk types 16, 18, 31,
33, 35, 45, 51, 52 and 56), is available for re-
search use only (Digene Diagnostics, Inc.).
The specimens for HPV testing were collected
with Christmas-tree cytobrushes at the same time
the cytology smears were prepared in order to en-
sure that the cells were obtained from the same site.
Each set of patient samples was combined, mixed,
and reallocated to minimize sampling error. The
collection of 3 specimens probably accounted for
the high number of specimens with blood, i.e.,
54/172 cervical specimens. Although Bartholoma
et al.
15 utilized bloody specimens in their evalua-
tion of Oncor 32p-labeled probes vs. the Digene
ViraPap 32p-labeled probes for HPV screening,
they extracted and precipitated theDNA first. This
procedure, however, was not endorsed by Digene
(personal communication). Retrospectively, 2 visi-
bly bloody SB-positive specimens were tested by
DB; both were positive. Due to the current recom-
mendation by many cytopathologists, cytobrushes
were used to collect the specimens. Other studies have
utilized swabs rather than brushes, which might have
accounted for a report of decreased sensitivity of the
SB compared with the DB procedure.
16
Of the 109 specimens tested in parallel, 97.3%
were concordant for the presence and type ofHPV.
These findings are considerably higher than those
ofBurmer et al.,
17 Kiviat et al.,
18 and Bartholoma
et al.,
15 who reported a concordance of 66% (102/
154 specimens), 68% (62/91 specimens), and
7 8.7% (48/61 specimens), respectively. They also
reported a higher number of positive specimens:
45/154 (29%),
19 91/450 (20%),
2 and 31/61
(50.8%)
15 specimens vs. 13/179 (7.3%) positive
specimens obtained in this study. The low percent
of positive specimens in this study probably reflects
the patient population selected. In contrast to other
studies, the majority of specimens (146/179) were
obtained from patients seen in a private OB/GYN
practice. In concordance with the findings of Bar-
tholoma et al.,
15 all biopsies tested were DB and SB
positive.
Kiviat et al.
18 compared the ViraPap DB and SB
using 32p-labeled probes. They reported sensitiv-
ity, specificity, and positive and negative predictive
values of 90%, 94%, 74%, and 98%, respectively,
which compares favorably with the results obtained
in this study.
Six of the 9 positive cervical specimens were
positive by both DB and SB in this study. Two of 3
specimens positive by DB only had corresponding
positive Papanicolaou smears. Although reports
have suggested that biotinylated probes are not as
sensitive as the 32p-labeled probes in the DB proce-
dure, they appear to have equal sensitivity and spec-
ificity in the SB procedure. 6’21 The remaining spec-
imen that was positive by DB for types 31/33/35
and SB negative had a correpsonding negative Pa-
panicolaou smear.
Only 11/21 (52.4%) of the hybridization and
cervical biopsy histology results were concordant.
Seven of the remaining histology results were posi-
tive, even though the I-IPVDNA results were neg-
ative. This may reflect a lack of sensitivity on the
part of the DB and SB assays or perhaps a sampling
variation. Due to the limited number of biopsies,
we were unable to draw any conclusions.
Although SB is considered the gold standard
based on its greater sensitivity and specificity, 21’22
when the results from the Oncor SB using 32p_
labeled probes were compared with the ViraPap
DB, it was reported to be less sensitive. 15’18 Per-
haps this observation was due to a loss of DNA
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during the extraction and transfer steps of the SB
procedure, particularly if only a small quantity of
DNA was present in the specimen. Whether our
findings are consistent with Bartholoma et al.
is and
Kiviat et al.
18 or the 3 specimens that were positive
by DB were, in fact, true positives cannot be deter-
mined with certainty. These specimens will be tested
by a hybrid-capture chemiluminescent procedure
(Digene Diagnostics, Inc.) (manuscript in prepa-
ration), a new 6-h procedure for detecting HPV
DNA.
Bartholoma et al.
15 compared the results from
cervical specimens using the Oncor SB 32p-labeled
probes, and the ViraPap DB. Seventy-four percent
(37/50 specimens) compared favorably. The dis-
crepancies resulted from a lack of detection of I--IPV
types 31/33/35 by SB. Eight specimens were posi-
tive by DB for types 31/33/3 5 and negative by the
Oncor SB. One of these DB-positive specimens,
which gave bands by SB, may have represented a
cross-reaction, e.g., HPV type 16 shares a region
ofDNA homology with type 31.
In this study, the 3 discrepant specimens were
deemed adequate during the microscopic-quality
assessment procedure. The sampling variations
were minimized or eliminated by combining the
paired specimens and then distributing them in
equal volumes for DB and SB testing. To avoid
interobserver variation, each SB and DB test re-
sult was evaluated independently by 2 observers
without prior clinical or Papanicolaou-smear infor-
mation. A third individual was responsible forcod-
ing the specimens prior to testing. There was 100%
concordance of interpretations by the observers.
Weintraub et al.
23 compared the ViraType and
cytology results and reported a concordance of 56%
and a sensitivity and specificity of 48% and 77%,
respectively. These results were similar to our find-
ings, i.e., 84.2% concordance, 44.4% sensitivity,
and 87.6% specificity, emphasizing the lack of pre-
dictability of the Papanicolaou smears for HPV
infection. Although 19/169 Papanicolaou smears
were reported as SIL-L, none was interpreted as
SIL-I-I or CIS. Interestingly, 2 patients with pre-
vious normal Papanicolaou smears had smears
showing squamous atypia and SIL-L. Both were
positive for type 18 or 16/18. Infection with type
18 has been reported to occur in younger age groups
(8-12 years old), cause a higher recurrence rate,
and have the potential to rapidly progress to CIS
11 within year.
Two of the 13 specimens (15.4%) were multiply
infected with HPV. One biopsy was positive for
I-IPV types 6, 16, and 33 and the second biopsy was
positive for types 6 and 16. Dual infections are not
unusual
14 and may represent exposure to multiple
partners. Burmer et al.
17 reported a rate of 12% of
multiple infections in their patient population.
Our study did not support the observation that
an early onset of sexual relations increases the risk
ofHPV infection. However, only 42/172 patients
enrolled in this study had their first sexual relations
between 13 and 16 years of age. The only risk
factor identified in this study was the number of
sexual partners. Finding an association with the
number of sexual partners is remarkable, consider-
ing the sample size.
In conclusion, the detection ofHPV and identi-
fication of the specific type may have significant
diagnostic and prognostic implications. To date,
these viruses cannot be isolated in cell culture due to
the requirement for cell differentiation in a produc-
tive or permissive infection, nor can serology be
employed to provide a laboratory diagnosis. More
sophisticated molecular diagnostic techniques have
been developed utilizing DNA hybridization in
order to detect this unique group of viruses.
Several testing formats are currently available
for HPV DNA detection. The test method that is
chosen should be easy to use, involve a reasonable
turnaround time and minimal hands-on, employ
a non-radioisotopic label for the probes, and pro-
vide excellent sensitivity, specificity, and predic-
tive values, all at a reasonable cost. Although nei-
ther of the kits employed in this study fulfills all of
these requirements, both methods have acceptable
sensitivity, specificity, and predictive values when
compared with cytology. Each kit has advantages
and disadvantages. Both kits are designed for batch-
ing specimens due to the cost associated with the
reagents, as well as the hands-on and turnaround
time from start to finish of each run. With the
implementation of stringent cost-containment pro-
grams throughout the country and decreases in lab-
oratory staff in many hospitals, HPV testing may
be considered in the following select cases: 1) his-
tory of another sexually transmitted disease, 2)
equivocal Papanicolaou smear, 3) history of multi-
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pie sexual partners, and 4) immunocompromised
status.
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